세계의 맞춤형 의료 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Personalized Medicine Market Size, Share & Trends Analysis Report By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics), By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,649,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,103,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,010,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

맞춤형 의료 시장 개요

세계 맞춤형 의료 시장 규모는 2024년 5,671억 달러로 평가되었습니다. 2033년에는 1조 1,961억 8,000만 달러에 달하고, 2025-2033년 CAGR은 8.80%를 보일 것으로 예측됩니다. 표적 치료와 정밀 진단에 대한 수요가 증가하면서 맞춤형 의료 시장 확대에 큰 힘을 보태고 있습니다.

유전체 기술, 바이오마커 식별, 데이터 기반 치료 전략의 발전으로 의료진은 환자 개개인에 맞는 맞춤형 치료를 할 수 있게 되었습니다. 이 접근법은 치료 효과를 높이고 부작용을 최소화하며 의료 자원의 효율적인 활용을 지원합니다. 전 세계적으로 만성질환과 복합질환이 증가함에 따라 개인 맞춤형 솔루션에 대한 관심이 높아지면서 진단, 치료, 건강 데이터 통합 플랫폼 전반에 걸친 혁신과 투자가 촉진되고 있습니다. 암, 당뇨병, 심혈관 질환과 같은 만성 질환 증가로 인해 의료 서비스 제공업체들은 개인 맞춤형 치료 전략을 시행하고 있습니다.

개인 맞춤형 진단은 보다 높은 정확도로 질병을 식별하고, 조기 개입과 임상 결과를 개선할 수 있습니다. 2024년, Illumina가 FDA 승인을 받은 TruSight Oncology Comprehensive 검사가 500개 이상의 유전자를 분석하여 표적 암 치료의 지침이 된 것처럼, 개인 맞춤형 진단은 질병을 식별하는 데 있어 더 높은 정확도를 가져왔습니다. 유전적 소인에 대한 환자들의 인식이 높아지면서 DNA 기반 검사 서비스의 보급을 뒷받침하고 있습니다. 능동적이고 환자 중심의 케어 모델을 지향하는 이러한 움직임은 의료 영역 전반에 걸쳐 시장의 잠재력을 계속 확장하고 있습니다.

유전체학, 인공지능, 데이터 분석의 기술 발전은 맞춤형 의료 시장의 성장을 더욱 촉진할 것입니다. 차세대 염기서열 분석기, 바이오마커 탐색, 바이오인포매틱스를 활용하여 환자 개개인프로파일에 맞는 혁신적인 솔루션을 개발하고 있습니다. AI를 임상 의사결정에 통합함으로써 복잡한 데이터 세트의 신속한 분석이 가능해져 진단의 정확성과 치료법 선택이 향상되고 있습니다. 원격의료 플랫폼과 의료 IT 시스템은 특히 만성질환 관리에서 개인 맞춤형 진료에 대한 원격 접근을 용이하게 합니다. 이러한 기술 혁신은 의료 서비스 제공을 재구성하고, 맞춤형 접근 방식의 확장 가능한 도입을 지원하고 있습니다.

민간 부문의 투자와 전략적 제휴 증가도 시장 모멘텀에 기여하고 있습니다. 제약회사는 진단약 기업과 제휴하여 표적치료제 동반진단약을 공동개발하고 있습니다. 스타트업과 생명공학 기업들은 혁신적인 영양, 웰니스, 유전체학 제품을 제공하며 시장에 진입하고 있습니다. 건강 최적화 및 예방 의료에 대한 소비자의 관심이 높아지면서 소비자 직접 검사 및 맞춤형 웰니스 플랜에 대한 수요가 증가하고 있습니다. 시장 경쟁력을 강화하기 위해 각 기업은 제품 차별화, 데이터 기반 전략, 세계 진출에 집중하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 맞춤형 의료 시장 변수, 동향 및 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter의 Five Forces 분석
  • PESTLE 분석
  • 파이프라인 분석
  • 특허 만료 분석
  • 가격 분석

제4장 맞춤형 의료 시장 : 제품 비즈니스 분석

• 제품 시장 점유율, 2024년 & 2033년
• 제품 부문 대시보드
• 시장 규모와 예측과 동향 분석(제품별, 2021-2033년)
• 맞춤형 의료 진단
• 맞춤형 의료 치료
• 맞춤형 의료
• 맞춤 영양 및 건강

제5장 맞춤형 의료 시장 : 최종 용도 비즈니스 분석

• 최종 용도 시장 점유율, 2024년 & 2033년
• 최종 용도 부문 대시보드
• 시장 규모, 예측, 동향 분석(최종 용도별, 2021-2033년)
• 병원
• 진단센터
• 연구 및 학술기관
• 기타

제6장 맞춤형 의료 시장 : 지역별, 추정 및 동향 분석

• 지역별 시장 점유율 분석, 2024년 & 2033년
• 지역별 시장 대시보드
• 시장 규모와 예측 동향 분석, 2021-2033년
• 북미
  • 국가별, 2021-2033년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 참가자 개요
• 기업 시장 현황 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장기업
  • GE Healthcare
  • Illumina, Inc.
  • ASURAGEN, INC.
  • Abbott
  • Dako A/S
  • Exact Sciences Corporation
  • Danaher Corporation(Cepheid, Inc.)
  • Decode Genetics, Inc.
  • QIAGEN
  • Exagen Inc.
  • Precision Biologics
  • Celera Diagnostics LLC.
  • Biogen
  • Genelex
  • International Business Machines Corporation(IBM)
  • Genentech, Inc.

LSH

영문 목차

영문목차

Personalized Medicine Market Summary

The global personalized medicine market size was estimated at USD 567.10 billion in 2024 and is projected to reach USD 1,196.18 billion by 2033, growing at a CAGR of 8.80% from 2025 to 2033. The growing demand for targeted therapies and precision diagnostics is significantly driving the expansion of the personalized medicine market.

Advances in genomic technologies, biomarker identification, and data-driven treatment strategies enable healthcare providers to tailor therapies to individual patient profiles. This approach enhances treatment efficacy, minimizes adverse effects, and supports more efficient use of healthcare resources. As chronic and complex diseases rise globally, the focus on personalized solutions continues to strengthen, fostering innovation and investment across diagnostics, therapeutics, and health data integration platforms. The rise in chronic conditions such as cancer, diabetes, and cardiovascular diseases is prompting healthcare providers to implement individualized treatment strategies.

Personalized diagnostics deliver greater accuracy in disease identification, leading to earlier intervention and better clinical outcomes. Personalized diagnostics delivered greater accuracy in disease identification, as in 2024 when Illumina's FDA approved TruSight Oncology Comprehensive test analyzed over 500 genes to guide targeted cancer treatments. The increasing awareness among patients of genetic predispositions supports the uptake of DNA-based testing services. This movement toward proactive, patient-specific care models continues to expand the market's potential across medical domains.

Technological advancements in genomics, artificial intelligence, and data analytics further fuel growth in the personalized medicine market. Companies are leveraging next-generation sequencing, biomarker discovery, and bioinformatics to develop innovative solutions tailored to individual patient profiles. AI integration into clinical decision-making is enabling faster analysis of complex datasets, enhancing diagnostic precision and therapy selection. Telemedicine platforms and health IT systems facilitate remote access to personalized care, especially in chronic disease management. These technological innovations are reshaping healthcare delivery and supporting the scalable adoption of customized approaches.

Increasing private sector investments and strategic collaborations are also contributing to market momentum. Pharmaceutical companies are partnering with diagnostics firms to co-develop companion diagnostics for targeted therapies. Startups and biotech firms are entering the market with innovative nutrition, wellness, and genomics offerings. Expanding consumer interest in health optimization and preventive care is boosting demand for direct-to-consumer testing and customized wellness plans. Market players focus on product differentiation, data-driven strategies, and global expansion to strengthen their competitive positions.

Global Personalized Medicine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global personalized medicine market report based on product, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Personalized Medicine Diagnostics
  • Genetic Testing
  • Direct-To-Consumer (DTC) Diagnostics
  • Esoteric Lab Services
  • Esoteric Lab Tests
• Personalized Medicine Therapeutics
  • Pharmaceutical
  • Genomic Medicine
  • Medical Devices
• Personalized Medical Care
  • Telemedicine
  • Health Information Technology
• Personalized Nutrition & Wellness
  • Retail Nutrition
  • Complementary & Alternative Medicine
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Centers
• Research & Academic Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Personalized Medicine Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Personalized Medicine Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2033
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Personalized Medicine Diagnostics
  • 4.4.1. Personalized Medicine Diagnostics Market, 2021 - 2033 (USD Million)
  • 4.4.2. Genetic Testing
    • 4.4.2.1. Genetic Testing Market, 2021 - 2033 (USD Million)
  • 4.4.3. Direct-To-Consumer (DTC) Diagnostics
    • 4.4.3.1. Direct-To-Consumer (DTC) Diagnostics Market, 2021 - 2033 (USD Million)
  • 4.4.4. Esoteric Lab Services
    • 4.4.4.1. Esoteric Lab Services Market, 2021 - 2033 (USD Million)
  • 4.4.5. Esoteric Lab Tests
    • 4.4.5.1. Esoteric Lab Tests Market, 2021 - 2033 (USD Million)
• 4.5. Personalized Medicine Therapeutics
  • 4.5.1. Personalized Medicine Therapeutics Market, 2021 - 2033 (USD Million)
  • 4.5.2. Pharmaceutical
    • 4.5.2.1. Pharmaceutical Market, 2021 - 2033 (USD Million)
  • 4.5.3. Genomic Medicine
    • 4.5.3.1. Genomic Medicine Market, 2021 - 2033 (USD Million)
  • 4.5.4. Medical Devices
    • 4.5.4.1. Medical Devices Market, 2021 - 2033 (USD Million)
• 4.6. Personalized Medical Care
  • 4.6.1. Personalized Medical Care Market, 2021 - 2033 (USD Million)
  • 4.6.2. Telemedicine
    • 4.6.2.1. Telemedicine Market, 2021 - 2033 (USD Million)
  • 4.6.3. Health Information Technology
    • 4.6.3.1. Health Information Technology Market, 2021 - 2033 (USD Million)
• 4.7. Personalized Nutrition & Wellness
  • 4.7.1. Personalized Nutrition & Wellness Market, 2021 - 2033 (USD Million)
  • 4.7.2. Retail Nutrition
    • 4.7.2.1. Retail Nutrition Market, 2021 - 2033 (USD Million)
  • 4.7.3. Complementary & Alternative Medicine
    • 4.7.3.1. Complementary & Alternative Medicine Market, 2021 - 2033 (USD Million)

Chapter 5. Personalized Medicine Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2033
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End use, 2021 to 2033 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
• 5.5. Diagnostic Centers
  • 5.5.1. Diagnostic Centers Market, 2021 - 2033 (USD Million)
• 5.6. Research & Academic Institutes
  • 5.6.1. Research & Academic Institutes Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Personalized Medicine Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 6.4. North America
  • 6.4.1. North America Personalized Medicine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. End Use Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. End Use Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. U.S. Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. End Use Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. End Use Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. Uk Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. End Use Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. End Use Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. End Use Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. End Use Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. End Use Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. End Use Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. End Use Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. End Use Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. End Use Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. End Use Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. End Use Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. End Use Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. End Use Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. End Use Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Japan Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. End Use Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. China Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. End Use Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. End Use Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. End Use Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. End Use Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. GE Healthcare
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Illumina, Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. ASURAGEN, INC.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Abbott
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Dako A/S
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Exact Sciences Corporation
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Danaher Corporation (Cepheid, Inc.)
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Decode Genetics, Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. QIAGEN
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Exagen Inc.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Precision Biologics
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives
  • 7.5.12. Celera Diagnostics LLC.
    • 7.5.12.1. Overview
    • 7.5.12.2. Financial Performance
    • 7.5.12.3. Product Benchmarking
  • 7.5.13. Biogen
    • 7.5.13.1. Overview
    • 7.5.13.2. Financial Performance
    • 7.5.13.3. Product Benchmarking
  • 7.5.14. Genelex
    • 7.5.14.1. Overview
    • 7.5.14.2. Financial Performance
    • 7.5.14.3. Product Benchmarking
  • 7.5.15. International Business Machines Corporation (IBM)
    • 7.5.15.1. Overview
    • 7.5.15.2. Financial Performance
    • 7.5.15.3. Product Benchmarking
  • 7.5.16. Genentech, Inc.
    • 7.5.16.1. Overview
    • 7.5.16.2. Financial Performance
    • 7.5.16.3. Product Benchmarking

관련자료